-
2025-521865-29-00
4
2026-04-30
moderate-to-severe hidradenitis suppurativa
-
2025-522878-36-00
5
2026-04-20
Chronic Spontaneous Urticaria
-
2025-523342-27-00
4
2026-04-10
Alopecia areata
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2025-521251-24-00
4
2025-12-01
Non-Small cell lung cancer (NSCLC)
-
2024-512922-27-00
4
2025-11-25
Mantle Cell Lymphoma (MCL)
-
2023-508547-51-00
5
2025-11-18
Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoco
-
2024-519795-11-00
4
2025-10-06
Atopic Dermatitis
-
2023-505918-14-00
5
2025-07-16
Aetiological treatment of moderate to severe rhinitis/rhinoconjunctivi
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-515706-77-00
5
2025-05-08
Moderate to Severe Plaque Psoriasis
-
2023-507936-20-00
5
2025-05-05
Acute myeloid leukemia
-
2024-514517-35-00
5
2025-02-27
Acute myeloid leukemia
-
2024-512126-29-00
5
2025-02-25
Generalized Myasthenia Gravis
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2023-509877-22-00
5
2024-10-30
severe von Willebrand Disease
-
2023-505802-40-02
6
2024-10-09
glaucoma
-
2023-509606-30-00
5
2024-07-24
Ulcerative colitis
-
2023-508441-41-00
6
2024-07-08
Bacteriemia producida por P. aeruginosa.